Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PENUMBRA, INC.

(PEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Insider Sell: Penumbra

09/07/2021 | 10:00am EDT


© MT Newswires 2021
All news about PENUMBRA, INC.
10/07PENUMBRA INC : Completion of Acquisition or Disposition of Assets, Unregistered Sale of Eq..
AQ
10/06PENUMBRA, INC. : Schedules Third Quarter 2021 Earnings Release and Conference Call for Nov..
PR
10/06INSIDER SELL : Penumbra
MT
10/01Penumbra, Inc. completed the acquisition of Sixense Enterprises Inc. for approximately ..
CI
09/22PENUMBRA INC : Unregistered Sale of Equity Securities (form 8-K)
AQ
09/22PEN INVESTOR NOTICE : ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Penumbra, Inc..
PR
09/22Penumbra, Inc. entered into an agreement to acquire Sixense Enterprises Inc. for approx..
CI
09/20SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Penum..
PR
09/16INSIDER SELL : Penumbra
MT
09/16PENUMBRA : Truist Securities Starts Penumbra at Buy With $350 Price Target
MT
More news
Analyst Recommendations on PENUMBRA, INC.
More recommendations
Financials (USD)
Sales 2021 727 M - -
Net income 2021 35,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 282x
Yield 2021 -
Capitalization 9 794 M 9 794 M -
Capi. / Sales 2021 13,5x
Capi. / Sales 2022 11,5x
Nbr of Employees 3 300
Free-Float 95,5%
Chart PENUMBRA, INC.
Duration : Period :
Penumbra, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PENUMBRA, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 267,75 $
Average target price 323,43 $
Spread / Average Target 20,8%
EPS Revisions
Managers and Directors
Adam Elsesser Chairman, President & Chief Executive Officer
Maggie S. Yuen Chief Financial Officer
Pankaj Tiwari Vice President-Information Technology
Michaella Corso Vice President-Clinical Affairs
Corey L. Teigen Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
PENUMBRA, INC.53.00%9 794
MASIMO CORPORATION6.61%15 753
GETINGE AB94.85%11 840
NOVOCURE LIMITED-35.15%11 605
ASAHI INTECC CO., LTD.-21.70%7 013
SHOCKWAVE MEDICAL, INC.86.64%6 804